Brown Advisory
FATE icon

Brown Advisory’s Fate Therapeutics FATE Stock Holding History

Brown Advisory’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,338
Closed -$63.4K – 1275
2024
Q2 		$63.4K Hold
19,338
– – ﹤0.01% 1208
2024
Q1 		$142K Sell
19,338
-26
-0.1% -$161 ﹤0.01% 1198
2023
Q4 		$72.4K Hold
19,364
– – ﹤0.01% 1195
2023
Q3 		$41.1K Buy
19,364
+6,735
+53% +$22.3K ﹤0.01% 1173
2023
Q2 		$60.1K Buy
+12,629
New +$69.7K ﹤0.01% 1160
2023
Q1 		– Sell
-10,949
Closed -$110K – 1225
2022
Q4 		$110K Sell
10,949
-508,942
-98% -$9.56M ﹤0.01% 1164
2022
Q3 		$11.7M Buy
519,891
+4,859
+0.9% +$140K 0.02% 360
2022
Q2 		$12.8M Buy
515,032
+11,635
+2% +$321K 0.02% 349
2022
Q1 		$19.5M Buy
503,397
+236,931
+89% +$9.17M 0.03% 323
2021
Q4 		$15.6M Buy
+266,466
New +$15.1M 0.02% 355

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Brown Advisory's FATE Position: Q3 2024 in Review

Brown Advisory sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 19,338 shares — an estimated $63.4K sold.

Brown Advisory first reported a position in FATE in Q4 2021 and held it in 10 quarters. The position peaked at $19.5M in Q1 2022. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • Brown Advisory reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Brown Advisory sold 19,338 Fate Therapeutics shares in Q3 2024, an estimated $63.4K.
  • Brown Advisory first reported a position in Fate Therapeutics in Q4 2021 and held it in 10 quarters.
  • Brown Advisory's Fate Therapeutics position peaked at $19.5M in Q1 2022.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Brown Advisory's 13F filing for Q3 2024, filed 13 Nov 2024.